PDE9A and early-onset autosomal dominant Alzheimer disease: Bay 73-6691, an inaugural phosphodiesterase inhibitor selective for the PDE9A subtype, has previously been employed in studies to ameliorate memory deficits and cognitive impairments in Alzheimer’s disease.